This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drugdevelopment. It demands a comprehensive, collaborative approach that reduces complexity and allows for just-in-time decision-making throughout the drugdevelopment journey. billion in 2023 to 1.2
It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. Long-term sustainability may benefit from identifying priority indications, exploring emerging mechanisms of action and refining development priorities.
Altasciences At CPHI Americas 2025 pmjackson Thu, 07/03/2025 - 13:41 In the ever-changing drugdevelopment world, staying agile is essential to enabling more informed decisions, faster. It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve. Why does that matter?
Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drugdevelopment lifecycle. This was seen in the case of the BRAF V600E mutation test for melanoma patients receiving vemurafenib.
Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional smallmoleculedrug alternatives. 3D rendering of Antibody Drug Conjugate Molecules.
Drugdevelopment is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.
Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in smallmoleculedrug discovery. These core ADMET properties are fundamental to drugdevelopment across the industry, making them well-suited for pre-competitive collaboration.
Artificial Intelligence (AI) is poised to transform the field of target discovery in drugdevelopment, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. With support from pharmaceutical companies, ultimately, the answer to this question should be yes.
As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted smallmolecules aimed at revolutionising cancer treatment. Gender diversity is a hot topic in pharmaceutical and biotech drugdevelopment.
Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drugdevelopment for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. One approach is to look beyond the traditional drugmolecule.
Combining Broad’s expertise in cancer biology and state-of-the-art drug discovery methods with Bayer’s expertise in drugdevelopment greatly increases our power to bring transformative medicines to cancer patients.” “We “Through this alliance, Broad and Bayer have done just that.
Mass spectrometry imaging (MSI) enables the direct detection and quantitation of active pharmaceutical ingredients (APIs) and metabolites within tissue sections, making it widely regarded as a promising technique in the field of pharmacology and toxicology. For instance, Cheng et al.
Developingpharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drugdevelopment and facilitating faster access to new therapies.
In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Strategies to Tackle PPIs Despite these challenges, some wins in targeting PPIs with smallmolecules have emerged.
We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drugdevelopment process which promises to completely transform how we developdrugs with increases in productivity of an order of magnitude or more. One final parallel to 2001.
I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials.
Process validation is a critical regulatory requirement in pharmaceutical manufacturing. In the case of urgent or immediate public interest, process validation may be conducted concurrently with manufacturing the commercial smallmolecule or biologic product to expedite product availability for patients.
There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. 1 With this growth comes increased demands for laboratory services at all steps across the development process.
11, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. executive vice president of research and development. About Lexicon Pharmaceuticals. THE WOODLANDS, Texas, Dec. About LX9211.
Also, many companies never reached the point where they received validation from big pharmaceutical companies. Transplanting cells could prove to be more beneficial than treating a particular condition with a smallmolecule or an antibody, and that really speaks to the power of cell therapy. from May 2017 until December 2022.
1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 1] [2] It was developed by Vertex Pharmaceuticals , [5] and was approved for medical use in the United States in January 2025. [2] The FDA granted approval of Journavx to Vertex Pharmaceuticals Incorporated.
Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA smallmolecule for the treatment of prostate cancer. Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. Noria) and PSMA Therapeutics Inc.
As drugmolecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. HELSINKI , Nov. ” Prof.
During the development of new smallmoleculedrug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. Global regulatory agencies, including the U.S. Contact us to learn more today! link] ICH M7 (R2)- Q&A. link] ICH Q3A (R2).
In recent years, AA has followed in the footsteps of other dermatology indications — including psoriasis and atopic dermatitis — with growing research and clinical studies focusing on smallmolecules with broad cellular effects (JAK and PDE4 inhibitors) and cytokine-specific molecules antagonists (IL-23, Th2 and IL17) to treat the condition.
Algae – an overlooked resource for new therapies It is only in recent years that algae research has expanded beyond their potential for producing biodiesel, to also consider them as a bio-resource, not only for novel prebiotics but also for compounds with unique structures and pharmaceutically relevant bioactivities.
Since poorly soluble drugs are difficult to formulate as tablets, formulation scientists are looking to two-piece, liquid-filled hard-shell capsules as a solution. “As Because of these qualities, liquid-filled hard capsules offer a great opportunity for line extensions, and brand differentiation, in the competitive pharma market.
DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Greg possesses a wealth of experience in developing new cancer therapeutics across multiple U.S. Berk, MD, to its Board of Directors.
Vatiquinone, developed from PTC’s Bio-e platform, is an investigational oral smallmolecule that inhibits 15-Lipoxygenase, a key enzyme that regulates oxidative stress and inflammation response pathways underpinning many neurological disease pathologies, including epilepsy.
About PTC Therapeutics, Inc.
At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We
EVOTEC TO SUPPORT RAPPTA IN DEVELOPINGSMALLMOLECULES THAT REACTIVATE PP2A, A KEY TUMOR SUPPRESSOR.
THE COLLABORATION LEVERAGES EVOTEC’S ONCOLOGY EXPERTISE AND INTEGRATED DRUG DISCOVERY AND DEVELOPMENT PLATFORM.
For more information, go to www.rappta-therapeutics.com.
(hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation. CHIPCREEN BIOSCIENCES remains as the owner and manufacturer of the drug. in 19 provinces and regions in China.
According to preliminary data from one Phase 1 and two Phase 2 clinical trials reported by Vertex Pharmaceuticals Inc., Now this strategy is really paying off for the 90 percent of patients who have at least one copy of F508del.
The treatments all use the antisense technology and automation techniques developed at Ionis Pharmaceuticals , which Crooke founded. As Crooke explained, “With smallmolecules, if you make any chemical change, you have a new ballgame. That’s not the case with RNA-targeted drugs. We’re the middleman,” he said.
Cresset delivers software solutions and contract research expertise enabling companies around the world to accelerate their smallmolecule discovery processes efficiently and effectively. Customers include the pharmaceutical, biotechnology and agrochemical industries. Another concern surrounds ethical issues.
Our South San Francisco office at Oyster Point To bolster our stateside presence, we appointed Dr David Lustig as Vice President of Business Development for the US, bringing his extensive experience of the pharmaceutical industry and commercialisation into the Sygnature fold.
Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. We can link smallmoleculedrugs to a payload that would enter in the cell and kill it.
Harini joined Serna Bio in early 2021 and has been an integral part of the multidisciplinary teamworking on target ID platform development to drug discovery. There, I supported AI-enabled DD efforts in their smallmolecule portfolio.
Approval demonstrates our ability to execute upon the entirety of the drugdevelopment and registration process. We believe this smallmolecule platform has the potential beyond actinic keratosis and are leveraging the platform to develop therapies for other oncology indications.”. and in Europe.
After a whirlwind tour of the cutting-edge robotics facility for high throughput screening of smallmolecules, she joined me and NCATS Director Dr. Chris Austin in announcing that, thanks to an innovative public-private partnership, an experimental drug originally developed to fight cancer is now showing promise against Alzheimer’s disease.
4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 12] Positron emission tomography imaging revealed that brain KORs were almost completely saturated by the drug 2.5 Drug Discovery. nM vs. 24.0
Workshop addresses oncology dose optimization across full span of development In a series of broad-ranging, frank discussions, attendees at a joint FDA-American Association of Cancer Research (AACR) workshop worked through opportunities and challenges for dose optimization across the span of cancer drugdevelopment activities.
Drugdevelopment is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.
Working closely with AWS experts in machine learning and analytics, we aim to provide our scientists and researchers with the insights they need to help deliver medical breakthroughs that change patients’ lives,” said Andrew McKillop, Vice President of Pharmaceutical Sciences, Worldwide Research, Development, and Medical at Pfizer.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content